Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. S...
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.